#United States #Caris Life Sciences #Irving #Dr. James Hamrick #Precision Oncology

Caris Appoints Dr. James Hamrick as Chairman of the Caris Precision Oncology Alliance

On December 17, 2024, Caris Life Sciences, recognized as a leader in the TechBio field and a pioneer in precision medicine, announced an important leadership change aimed at advancing innovation in cancer care. Dr. James Hamrick, MD, MPH, has been appointed as the new Chairman of the Caris Precision Oncology Alliance™ (Caris POA).

As the Chairman of the Caris POA, Dr. Hamrick will steer a rapidly expanding international network composed of elite cancer care centers and collaborative research groups. This alliance aims to enhance precision oncology and drive biomarker-driven research, ultimately striving to upgrade clinical outcomes for cancer patients. With 96 institutions, including 47 NCI-designated comprehensive cancer centers, in its ranks, the Caris POA provides its members access to an extensive database and an advanced artificial intelligence platform pioneered by Caris to facilitate groundbreaking research in cancer profiling and molecular testing.

George W. Sledge, Jr., MD, Caris’ Executive Vice President and Chief Medical Officer, expressed enthusiasm for Dr. Hamrick’s appointment. He stated, “We are thrilled to welcome James as the new Chairman of the Caris Precision Oncology Alliance, especially as we approach welcoming our 100th member. James’ extensive expertise in oncology and real-world data will propel the mission forward, fostering innovation and collaboration. I look forward to the remarkable advancements we will achieve together in improving patient outcomes and transforming cancer care.”

In response to his appointment, Dr. Hamrick commented, “Joining Caris, an exemplary organization that is highly regarded in both the medical and academic communities as a leader in precision medicine, is truly an honor. I am excited to collaborate with the Caris Precision Oncology Alliance network of leading cancer centers and dedicated cancer care professionals who are at the forefront of advancing precision medicine. Together, we will continue to push the boundaries of cancer care and improve patient outcomes.”

Before stepping into this significant role, Dr. Hamrick held the position of Vice President, Clinical Oncology for Flatiron Health. In that capacity, he led a dedicated team, encompassing doctors, nurses, and informatics specialists, all working towards enhancing products and services that support front-line clinicians across numerous cancer clinics throughout the United States.

Dr. Hamrick’s previous experience also includes serving as Chief of Medical Oncology and Hematology at Kaiser Permanente of Georgia and practicing medicine at Georgia Cancer Specialists. His contributions to the field of oncology extend to his involvement on the Georgia Center for Oncology Research and Education board, along with participation in multiple leadership councils at Kaiser Permanente.

Dr. Hamrick's credentials include board certifications in internal medicine, medical oncology, and hematology. He obtained both his MD and an MPH in Epidemiology from the University of North Carolina at Chapel Hill, followed by completing his residency and fellowship in hematology/oncology at the University of California, San Francisco.

About Caris Life Sciences

Caris Life Sciences is recognized as a leading next-generation AI TechBio company dedicated to revolutionizing healthcare through innovative solutions. The company focuses on precision medicine, developing groundbreaking approaches that harness the power of comprehensive molecular profiling, including Whole Exome and Whole Transcriptome Sequencing. By integrating advanced AI and machine learning algorithms, Caris has established a large-scale, multimodal database essential for unraveling the molecular complexity of diseases. This combination of profound sequencing capabilities, big data analytics, and AI technology positions Caris to significantly elevate the field of precision medicine in areas such as early detection, diagnosis, treatment selection, and drug development.

The company, founded with the mission to fulfill the potential of precision medicine, places immense value on its workforce, advocating for diversity and inclusivity across all aspects. Headquartered in Irving, Texas, Caris operates globally with offices in major cities including Phoenix, New York, Cambridge, Tokyo, and Basel. Through its distribution partners, Caris makes its innovative services accessible in regions across the U.S., Europe, and Asia. For further information regarding services and advancements, visit CarisLifeSciences.com.